LBA18 Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC): Additional analyses of DESTINY-Breast09 in key subgroups of interest

作者：S. Loibl, Z. Jiang, Romualdo Barroso‐Sousa, Y.H. Park, C. Saura Manich, MF Rimawi, A. Schneeweiss, M. Toi, S-A. Im, Zhen Tong, Umut Demırcı, C.M. Villarreal Garza, Chiun‐Sheng Huang, Toshimi Takano, V. Guarneri, S. Mondal, David T. Huang, Ailiang Zeng, S.M. Tolaney · 发表于：Annals of Oncology · 年份：2025 · DOI：10.1016/j.annonc.2025.09.028 · 被引用次数：4 · 研究领域：HER2/EGFR in Cancer Research、Cancer Treatment and Pharmacology、Advanced Breast Cancer Therapies